SG11202010235QA - Anti-ror antibody constructs - Google Patents
Anti-ror antibody constructsInfo
- Publication number
- SG11202010235QA SG11202010235QA SG11202010235QA SG11202010235QA SG11202010235QA SG 11202010235Q A SG11202010235Q A SG 11202010235QA SG 11202010235Q A SG11202010235Q A SG 11202010235QA SG 11202010235Q A SG11202010235Q A SG 11202010235QA SG 11202010235Q A SG11202010235Q A SG 11202010235QA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody constructs
- ror
- ror antibody
- constructs
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862659635P | 2018-04-18 | 2018-04-18 | |
PCT/US2019/028051 WO2019204564A1 (en) | 2018-04-18 | 2019-04-18 | Anti-ror antibody constructs |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202010235QA true SG11202010235QA (en) | 2020-11-27 |
Family
ID=68239890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202010235QA SG11202010235QA (en) | 2018-04-18 | 2019-04-18 | Anti-ror antibody constructs |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210155692A1 (en) |
EP (1) | EP3797122A4 (en) |
JP (2) | JP2021522162A (en) |
KR (1) | KR20200143470A (en) |
CN (1) | CN112384533A (en) |
AU (1) | AU2019256431A1 (en) |
BR (1) | BR112020021269A2 (en) |
CA (1) | CA3097704A1 (en) |
EA (1) | EA202092202A1 (en) |
IL (1) | IL278061A (en) |
MX (1) | MX2020010881A (en) |
PH (1) | PH12020551716A1 (en) |
SG (1) | SG11202010235QA (en) |
WO (1) | WO2019204564A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4384218A2 (en) * | 2021-08-09 | 2024-06-19 | Merck Patent GmbH | Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines |
AU2022376953A1 (en) | 2021-10-28 | 2024-05-02 | Lyell Immunopharma, Inc. | Methods for culturing cells expressing ror1-binding protein |
US20230295276A1 (en) * | 2022-03-18 | 2023-09-21 | Novascope Biochips Inc. | Antibody for porcine reproductive and respiratory syndrome virus and uses thereof |
WO2024025343A1 (en) * | 2022-07-26 | 2024-02-01 | (주)에임드바이오 | Anti-ror1 antibody and use thereof |
WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
GB202216284D0 (en) * | 2022-11-02 | 2022-12-14 | Ucl Business Ltd | Self-regulation |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2421899B1 (en) * | 2009-04-23 | 2016-06-08 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-human ror1 antibodies |
CN102712695B (en) * | 2009-12-18 | 2015-01-21 | 堪瑟拉公司 | Biological inhibitors of ROR1 capable of inducing cell death |
WO2011159847A2 (en) * | 2010-06-15 | 2011-12-22 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof |
CA2818992C (en) * | 2010-12-01 | 2021-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric rabbit/human ror1 antibodies |
CN104662044B (en) * | 2012-08-24 | 2018-10-30 | 加利福尼亚大学董事会 | For treating ROR1 cancers and inhibiting the antibody and vaccine that shift |
EP2789630A1 (en) * | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
CA2963696A1 (en) * | 2014-10-09 | 2016-04-14 | Engmab Ag | Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer |
ES2935274T3 (en) * | 2014-12-05 | 2023-03-03 | Merck Patent Gmbh | domain swapping antibody |
WO2016094873A2 (en) * | 2014-12-12 | 2016-06-16 | Emergent Product Development Seattle, Llc | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods |
TWI718118B (en) * | 2015-01-16 | 2021-02-11 | 美商奇諾治療有限公司 | Antibodies and chimeric antigen receptors specific for ror1 |
WO2016142768A1 (en) * | 2015-03-10 | 2016-09-15 | Eureka Therapeutics, Inc. | Ror2 antibody |
JP2018524284A (en) * | 2015-05-18 | 2018-08-30 | ユーリカ セラピューティックス, インコーポレイテッド | Anti-ROR1 antibody |
EP3405494A1 (en) * | 2016-01-20 | 2018-11-28 | The Scripps Research Institute | Ror2 antibody compositions and related methods |
AU2017209099A1 (en) * | 2016-01-22 | 2018-08-02 | Janssen Biotech, Inc. | Anti-ROR1 antibodies, ROR1 x CD3 bispecific antibodies, and methods of using the same |
-
2019
- 2019-04-18 AU AU2019256431A patent/AU2019256431A1/en active Pending
- 2019-04-18 US US17/048,549 patent/US20210155692A1/en active Pending
- 2019-04-18 CN CN201980040982.8A patent/CN112384533A/en active Pending
- 2019-04-18 EA EA202092202A patent/EA202092202A1/en unknown
- 2019-04-18 SG SG11202010235QA patent/SG11202010235QA/en unknown
- 2019-04-18 BR BR112020021269-5A patent/BR112020021269A2/en unknown
- 2019-04-18 CA CA3097704A patent/CA3097704A1/en active Pending
- 2019-04-18 JP JP2020556851A patent/JP2021522162A/en active Pending
- 2019-04-18 KR KR1020207032901A patent/KR20200143470A/en unknown
- 2019-04-18 WO PCT/US2019/028051 patent/WO2019204564A1/en unknown
- 2019-04-18 EP EP19789299.5A patent/EP3797122A4/en active Pending
- 2019-04-18 MX MX2020010881A patent/MX2020010881A/en unknown
-
2020
- 2020-10-14 IL IL278061A patent/IL278061A/en unknown
- 2020-10-16 PH PH12020551716A patent/PH12020551716A1/en unknown
-
2023
- 2023-10-04 JP JP2023172867A patent/JP2023168551A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2020010881A (en) | 2020-11-09 |
WO2019204564A1 (en) | 2019-10-24 |
KR20200143470A (en) | 2020-12-23 |
CN112384533A (en) | 2021-02-19 |
EA202092202A1 (en) | 2021-07-23 |
BR112020021269A2 (en) | 2021-03-16 |
IL278061A (en) | 2020-11-30 |
EP3797122A4 (en) | 2022-04-20 |
EP3797122A1 (en) | 2021-03-31 |
PH12020551716A1 (en) | 2021-07-26 |
JP2023168551A (en) | 2023-11-24 |
WO2019204564A9 (en) | 2019-12-12 |
US20210155692A1 (en) | 2021-05-27 |
JP2021522162A (en) | 2021-08-30 |
AU2019256431A1 (en) | 2020-11-05 |
CA3097704A1 (en) | 2019-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279321A (en) | Anti-sirpα antibody | |
SG11202106214YA (en) | Novel anti-ccr8 antibody | |
IL280780A (en) | Anti-tigit antibodies | |
IL279352A (en) | Il-11ra antibodies | |
IL280013A (en) | Anti-il36r antibodies | |
IL278010A (en) | Galectin-10 antibodies | |
IL278061A (en) | Anti-ror antibody constructs | |
IL266143A (en) | Antibody constructs | |
IL277030A (en) | Antibodies | |
SG11202106171WA (en) | Anti-btla antibodies | |
ZA202101177B (en) | Anti-btla antibody | |
GB201811368D0 (en) | Antibody | |
IL279399A (en) | Multi-specific antibody constructs | |
IL281594A (en) | Anti-klrg1 antibodies | |
GB201817172D0 (en) | Antibody | |
ZA202108836B (en) | Anti-epha4 antibody | |
EP4083211A4 (en) | Anti-cdcp1 antibody | |
GB201806084D0 (en) | Antibodies | |
IL271067B2 (en) | Anti-trkb antibodies | |
SG11202105718TA (en) | Modified antibodies | |
GB201819952D0 (en) | Antibodies | |
GB201817312D0 (en) | Antibodies | |
GB201817313D0 (en) | Antibodies | |
GB201817309D0 (en) | Antibodies | |
GB201817311D0 (en) | Antibodies |